NASDAQ:ACET - Aceto Stock Price, Price Target & More

$2.82 -4.58 (-61.89 %)
(As of 04/19/2018 11:06 AM ET)
Previous Close$7.40
Today's Range$2.60 - $3.25
52-Week Range$2.60 - $17.10
Volume3.45 million shs
Average Volume482,785 shs
Market Capitalization$226.72 million
P/E Ratio6.22
Dividend Yield3.53%

About Aceto (NASDAQ:ACET)

Aceto logoAceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products, and specialty chemicals. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment is also involved in developing and marketing generic pharmaceutical products. It sells its generic prescription and over the counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass market merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals for use in the manufacture of plastics, surface coatings, cosmetics and personal care products, textiles, and fuels and lubricants, as well as for food, flavor, paper, and film industries; dye and pigment intermediates used in the color-producing industries; and organic intermediates used in the production of agrochemicals. Its raw materials are also used in electronic parts for photo tooling, circuit boards, and production of computer chips. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.

Receive ACET News and Ratings via Email

Sign-up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Sub-IndustryTrading Companies & Distributors


Debt-to-Equity Ratio0.79%
Current Ratio2.00%
Quick Ratio1.38%


Trailing P/E Ratio6.22
Forward P/E Ratio2.76
P/E Growth0.72

Sales & Book Value

Annual Sales$638.32 million
Price / Sales0.14
Cash Flow$0.9338 per share
Price / Cash3.02
Book Value$13.54 per share
Price / Book0.21


EPS (Most Recent Fiscal Year)$1.19
Net Income$11.37 million
Net Margins-0.79%
Return on Equity10.26%
Return on Assets4.01%


Outstanding Shares30,760,000

How to Become a New Pot Stock Millionaire

Aceto (NASDAQ:ACET) Frequently Asked Questions

What is Aceto's stock symbol?

Aceto trades on the NASDAQ under the ticker symbol "ACET."

How often does Aceto pay dividends? What is the dividend yield for Aceto?

Aceto declared a quarterly dividend on Thursday, February 1st. Shareholders of record on Friday, March 9th will be paid a dividend of $0.065 per share on Friday, March 23rd. This represents a $0.26 dividend on an annualized basis and a dividend yield of 8.87%. The ex-dividend date of this dividend is Thursday, March 8th. View Aceto's Dividend History.

How were Aceto's earnings last quarter?

Aceto Co. (NASDAQ:ACET) posted its quarterly earnings data on Thursday, February, 1st. The company reported $0.22 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.23 by $0.01. The company earned $171.20 million during the quarter, compared to analysts' expectations of $176.50 million. Aceto had a positive return on equity of 10.26% and a negative net margin of 0.79%. The business's revenue was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 earnings per share. View Aceto's Earnings History.

When is Aceto's next earnings date?

Aceto is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Aceto.

What guidance has Aceto issued on next quarter's earnings?

Aceto updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.07. The company issued revenue guidance of +10-15% to ~701.8-733.7 million, compared to the consensus revenue estimate of $734.29 million.

What price target have analysts set for ACET?

1 brokerages have issued 12-month price targets for Aceto's shares. Their forecasts range from $13.00 to $13.00. On average, they expect Aceto's stock price to reach $13.00 in the next twelve months. View Analyst Ratings for Aceto.

What are Wall Street analysts saying about Aceto stock?

Here are some recent quotes from research analysts about Aceto stock:
  • 1. Canaccord Genuity analysts commented, "We are pleased with the appointment of Ed Borkowski as chief financial officer, as he brings a breadth of generics knowledge and experience that will likely help Aceto’s continued transition into a human health company. We like the turnaround potential for Aceto, but believe management will need to execute for a number of quarters before generating meaningful investor interest; we maintain our BUY rating on ACET shares. Roth’s retirement has been well telegraphed in parallel to the on-boarding of William Kennally as CEO. Douglas Roth has been CFO since 2001, and was a key leader in the transformation of Aceto from specialty chemicals/API to human health. After the appointment of Bill Kennally as CEO late last year, we expected Aceto to find a thoughtful, seasoned finance leader to complement Kennally’s experience, and see Borkowski as an excellent add." (2/16/2018)
  • 2. According to Zacks Investment Research, "Aceto Corporation markets, sells and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals. The company's operating segment consists of Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements. It markets and distributes its generic prescription and over the counter pharmaceutical products. Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates. Performance Chemicals segment provides specialty chemicals. It serves chemical, agricultural, human health and pharmaceutical industries. The company operates primarily in United States, Europe, and Asia. Aceto Corporation and is headquartered in Port Washington, New York. " (2/6/2018)

Who are some of Aceto's key competitors?

Who are Aceto's key executives?

Aceto's management team includes the folowing people:
  • Mr. William C. Kennally III, CEO & Director (Age 63)
  • Mr. Douglas Roth, Sr. VP, Chief Admin. Officer, Treasurer & Assistant Sec. (Age 61)
  • Mr. Walter J. Kaczmarek III, Chief Operating Officer (Age 59)
  • Mr. Frank DeBenedittis, SVP of Corp. Bus. Devel. & International SVP of Active Pharmaceutical Ingredients (Age 64)
  • Mr. Edward J. Borkowski, Chief Financial Officer (Age 60)

Has Aceto been receiving favorable news coverage?

News articles about ACET stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aceto earned a media sentiment score of 0.06 on Accern's scale. They also assigned press coverage about the company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Aceto?

Shares of ACET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aceto's stock price today?

One share of ACET stock can currently be purchased for approximately $2.93.

How big of a company is Aceto?

Aceto has a market capitalization of $226.72 million and generates $638.32 million in revenue each year. The company earns $11.37 million in net income (profit) each year or $1.19 on an earnings per share basis. Aceto employs 286 workers across the globe.

How can I contact Aceto?

Aceto's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company can be reached via phone at 516-627-6000 or via email at [email protected]

MarketBeat Community Rating for Aceto (ACET)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Aceto and other stocks. Vote "Outperform" if you believe ACET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACET will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aceto (NASDAQ:ACET) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Aceto in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 360.99%. The high price target for ACET is $13.00 and the low price target for ACET is $13.00. There are currently 1 sell rating for the stock, resulting in a consensus rating of "Sell."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: SellBuyHoldHold
Consensus Rating Score:
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$10.00$15.00$18.00
Price Target Upside: 360.99% upside38.12% upside51.98% upside58.87% upside

Aceto (NASDAQ:ACET) Consensus Price Target History

Price Target History for Aceto (NASDAQ:ACET)

Aceto (NASDAQ:ACET) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018Canaccord GenuityDowngradeBuy -> Sell$13.00HighView Rating Details
2/3/2017Craig HallumDowngradeBuy -> HoldN/AView Rating Details
1/31/2017First AnalysisDowngradeOverweight -> Equal WeightN/AView Rating Details
(Data available from 4/19/2016 forward)


Aceto (NASDAQ:ACET) Earnings History and Estimates Chart

Earnings by Quarter for Aceto (NASDAQ:ACET)

Aceto (NASDAQ:ACET) Earnings Estimates

2018 EPS Consensus Estimate: $1.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.23$0.32$0.28
Q2 20182$0.22$0.29$0.26
Q3 20182$0.25$0.34$0.30
Q4 20182$0.26$0.31$0.29
Q1 20191$0.29$0.29$0.29
Q2 20191$0.31$0.31$0.31

Aceto (NASDAQ ACET) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018Q2 2018$0.23$0.22$176.50 million$171.20 millionViewListenView Earnings Details
11/2/2017Q1 2018$0.28$0.30$190.58 million$185.26 millionViewN/AView Earnings Details
8/24/2017Q4 2017$0.44$0.27$184.49 million$194.60 millionViewN/AView Earnings Details
5/4/2017Q3 2017$0.44$0.39$195.09 million$190.10 millionViewListenView Earnings Details
2/2/2017Q2 2017$0.32$0.24$136.65 million$125.60 millionViewListenView Earnings Details
11/2/2016Q1 17$0.29$0.28$132.88 million$128.02 millionViewListenView Earnings Details
8/25/2016Q416$0.39$0.35$146.71 million$135.40 millionViewListenView Earnings Details
5/5/2016Q3$0.39$0.42$150.07 million$157.90 millionViewListenView Earnings Details
2/4/2016Q2$0.30$0.36$132.71 million$131.70 millionViewListenView Earnings Details
11/5/2015Q116$0.34$0.37$139.89 million$133.50 millionViewListenView Earnings Details
9/10/2015Q415$0.31$0.48$146.68 million$146.60 millionViewListenView Earnings Details
5/7/2015Q3$0.29$0.34$140.00 million$145.80 millionViewListenView Earnings Details
2/5/2015Q115$0.26$0.28$130.00 million$13.00 millionViewListenView Earnings Details
11/6/2014Q414$0.29$0.23$146.40 million$130.80 millionViewListenView Earnings Details
9/4/2014Q314$0.17$0.21$134.23 million$139.60 millionViewListenView Earnings Details
5/8/2014Q214$0.28$0.19$136.70 million$124.83 millionViewListenView Earnings Details
2/7/2014Q114$0.24$0.24$147.02 million$116.50 millionViewListenView Earnings Details
11/7/2013Q1 2014$0.40$129.26 millionViewN/AView Earnings Details
8/28/2013Q4 2013$0.20$0.19$113.10 million$123.10 millionViewListenView Earnings Details
5/9/2013Q3 2013$0.26$0.34$128.56 million$150.90 millionViewListenView Earnings Details
2/7/2013Q2 2013$0.20$0.17ViewN/AView Earnings Details
11/8/2012Q113$0.19$0.18$110.85 million$111.70 millionViewN/AView Earnings Details
9/6/2012Q4 2012$0.16$0.17ViewN/AView Earnings Details
5/3/2012Q3 2012$0.12$0.18ViewN/AView Earnings Details
2/9/2012Q2 2012$0.07$0.17ViewN/AView Earnings Details
11/3/2011Q1 2012$0.07$0.13ViewN/AView Earnings Details
9/9/2011Q4 2011$0.12$0.13ViewN/AView Earnings Details
5/6/2011Q3 2011$0.17$0.14ViewN/AView Earnings Details
2/4/2011Q2 2011$0.09$0.08ViewN/AView Earnings Details
11/5/2010Q1 2011$0.08$0.11ViewN/AView Earnings Details
9/10/2010Q4 2010$0.10$0.17ViewN/AView Earnings Details
5/7/2010Q3 2010$0.10$0.15ViewN/AView Earnings Details
2/5/2010Q2 2010$0.05($0.05)ViewN/AView Earnings Details
11/6/2009Q1 2010$0.06$0.04ViewN/AView Earnings Details
9/11/2009Q4 2009$0.11$0.04ViewN/AView Earnings Details
5/8/2009Q3 2009$0.12$0.08ViewN/AView Earnings Details
2/6/2009Q2 2009$0.06$0.04ViewN/AView Earnings Details
11/7/2008Q1 2009$0.15$0.18ViewN/AView Earnings Details
9/5/2008Q4 2008$0.19$0.32ViewN/AView Earnings Details
5/9/2008Q3 2008$0.05$0.13ViewN/AView Earnings Details
2/8/2008Q2 2008$0.04$0.04ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Aceto (NASDAQ:ACET) Dividend Information

Aceto pays an annual dividend of $0.26 per share, with a dividend yield of 9.22%. ACET's most recent quarterly dividend payment was Friday, March 23. Aceto pays out 21.85% of its earnings out as a dividend.
Most Recent Dividend:3/23/2018
Annual Dividend:$0.26
Dividend Yield:9.22%
Payout Ratio:21.85% (Trailing 12 Months of Earnings)
25.49% (Based on This Year's Estimates)
22.61% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Aceto (NASDAQ:ACET)

Aceto (NASDAQ:ACET) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aceto (NASDAQ ACET) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 76.27%
Insider Trading History for Aceto (NASDAQ:ACET)
Institutional Ownership by Quarter for Aceto (NASDAQ:ACET)

Aceto (NASDAQ ACET) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2017Frances P ScallyCAOSell309$10.44$3,225.9618,490View SEC Filing  
9/8/2017Steven RogersSVPSell2,000$10.34$20,680.0038,530View SEC Filing  
9/7/2017Salvatore J Sr Guccione SrInsiderSell218$10.48$2,284.64245,269View SEC Filing  
9/6/2017Albert L EilenderChairmanSell9,530$10.47$99,779.10307,028View SEC Filing  
9/6/2017Salvatore J Sr Guccione SrInsiderSell9,850$10.47$103,129.50241,262View SEC Filing  
9/6/2017Steven RogersSVPSell2,050$10.47$21,463.5040,495View SEC Filing  
9/5/2017Walter J Kaczmarek IIICOOSell2,635$10.57$27,851.9572,817View SEC Filing  
8/2/2017Walter J Kaczmarek IIICOOSell7,083$16.57$117,365.3147,917View SEC Filing  
7/6/2017Albert L EilenderChairmanSell6,500$15.21$98,865.00252,029View SEC Filing  
7/6/2017Frank DebenedittisInsiderSell2,089$15.28$31,919.9276,936View SEC Filing  
7/6/2017Salvatore J Sr Guccione SrCEOSell7,421$15.21$112,873.41190,662View SEC Filing  
7/5/2017Charles John AlaimoInsiderSell2,612$15.48$40,433.7615,017View SEC Filing  
7/5/2017Douglas A RothCFOSell5,075$15.47$78,510.2574,403View SEC Filing  
7/5/2017Steven RogersSVPSell2,285$15.45$35,303.2518,995View SEC Filing  
3/9/2017Frank DebenedittisInsiderSell3,600$14.94$53,784.0082,625View SEC Filing  
1/17/2017Daniel B YaroshDirectorSell891$20.69$18,434.798,179View SEC Filing  
12/9/2016Raymond BartoneInsiderSell5,000$21.54$107,700.0033,452View SEC Filing  
12/8/2016Nicolas I ShackleyInsiderSell2,500$21.27$53,175.0031,476View SEC Filing  
11/30/2016Frank DebenedittisInsiderSell7,040$20.22$142,348.8079,620View SEC Filing  
11/29/2016Satish SrinivasanCOOSell12,917$20.02$258,598.3420,434View SEC Filing  
11/28/2016Albert L EilenderChairmanSell18,500$19.88$367,780.00283,979View SEC Filing  
11/23/2016Steven RogersSVPSell2,400$19.53$46,872.0021,280View SEC Filing  
11/14/2016Hans C NoetzliDirectorSell6,000$18.32$109,920.0085,572View SEC Filing  
9/8/2016Salvatore J Sr Guccione SrInsiderSell260$19.64$5,106.40198,343View SEC Filing  
9/7/2016Charles John AlaimoInsiderSell25$19.43$485.7523,154View SEC Filing  
9/6/2016Albert L EilenderChairmanSell12,936$19.92$257,685.12236,649View SEC Filing  
9/6/2016Frank DebenedittisInsiderSell4,580$19.85$90,913.0076,995View SEC Filing  
9/6/2016Satish SrinivasanCOOSell3,980$19.84$78,963.2026,521View SEC Filing  
9/6/2016Steven RogersSVPSell2,167$20.04$43,426.6820,443View SEC Filing  
9/2/2016Charles John AlaimoInsiderSell2,567$19.85$50,954.9520,255View SEC Filing  
7/19/2016Satish SrinivasanCOOSell595$25.48$15,160.6015,521View SEC Filing  
7/7/2016Frank DebenedittisVPSell3,275$23.34$76,438.5067,495View SEC Filing  
7/6/2016Albert L EilenderChairmanSell7,690$22.53$173,255.70210,199View SEC Filing  
7/6/2016Charles John AlaimoSVPSell3,639$22.41$81,549.9911,755View SEC Filing  
7/6/2016Douglas A RothCFOSell6,770$22.72$153,814.4058,783View SEC Filing  
7/6/2016Salvatore J Sr Guccione SrCEOSell10,945$23.25$254,471.25144,042View SEC Filing  
7/6/2016Satish SrinivasanCOOSell3,250$22.80$74,100.0016,116View SEC Filing  
7/6/2016Steven RogersVPSell3,275$22.50$73,687.5011,943View SEC Filing  
6/7/2016Terry KippleyVPSell2,000$22.50$45,000.0019,249View SEC Filing  
6/7/2016William N BrittonDirectorSell4,200$23.12$97,104.0044,767View SEC Filing  
6/6/2016Frank DebenedittisVPSell6,810$22.63$154,110.3070,770View SEC Filing  
6/6/2016Satish SrinivasanCOOSell3,497$22.69$79,346.9319,366View SEC Filing  
5/31/2016Albert L EilenderChairmanSell9,881$22.21$219,457.01217,889View SEC Filing  
5/26/2016Douglas A RothCFOSell7,000$22.16$155,120.0065,553View SEC Filing  
3/10/2016Raymond BartoneSVPSell3,000$22.40$67,200.0032,109View SEC Filing  
3/8/2016Hans C NoetzliDirectorSell6,500$22.91$148,915.0085,873View SEC Filing  
3/2/2016Frank DebenedittisVPSell3,000$21.98$65,940.0077,580View SEC Filing  
3/1/2016Steven RogersVPSell2,100$21.82$45,822.0015,218View SEC Filing  
2/25/2016Albert L EilenderChairmanSell9,281$21.79$202,232.99237,051View SEC Filing  
2/23/2016Charles John AlaimoSVPSell4,750$21.91$104,072.5020,144View SEC Filing  
2/23/2016Douglas A RothCFOSell17,000$21.52$365,840.0084,553View SEC Filing  
12/9/2015Satish SrinivasanCOOSell3,000$27.02$81,060.0022,863View SEC Filing  
12/9/2015Terry KippleyVPSell1,550$27.06$41,943.0021,249View SEC Filing  
12/8/2015Nicolas I ShackleySVPSell3,000$26.70$80,100.0024,278View SEC Filing  
12/1/2015Charles John AlaimoSVPSell3,000$28.22$84,660.0018,644View SEC Filing  
11/25/2015Hans C. NoetzliDirectorSell3,000$27.52$82,560.0073,881View SEC Filing  
11/24/2015Steven RogersVPSell3,000$27.56$82,680.0017,318View SEC Filing  
10/15/2015Albert L. EilenderChairmanSell8,155$28.90$235,679.50227,770View SEC Filing  
9/10/2015Charles John AlaimoSVPSell1,620$22.14$35,866.8021,560View SEC Filing  
9/10/2015Douglas A. RothCFOSell6,250$22.14$138,375.0079,246View SEC Filing  
9/10/2015Frank DebenedittisVPSell2,553$22.14$56,523.4283,580View SEC Filing  
9/10/2015Salvatore J. Sr Guccione, Sr.CEOSell9,386$22.14$207,806.04154,712View SEC Filing  
7/2/2015Albert L EilenderChairmanSell10,938$24.20$264,699.60View SEC Filing  
7/2/2015Charles John AlaimoSVPSell2,998$24.19$72,521.62View SEC Filing  
7/2/2015Douglas A RothCFOSell5,748$24.19$139,044.12View SEC Filing  
7/2/2015Frank DebenedittisVPSell2,629$24.19$63,595.51View SEC Filing  
7/2/2015Salvatore J Sr Guccione SrCEOSell9,114$24.19$220,467.66View SEC Filing  
7/2/2015Satish SrinivasanCOOSell1,921$24.19$46,468.99View SEC Filing  
6/8/2015Raymond BartoneSVPSell5,000$24.44$122,200.00View SEC Filing  
6/3/2015Frank DebenedittisVPSell4,000$24.41$97,640.00View SEC Filing  
5/27/2015Charles John AlaimoSVPSell2,000$23.19$46,380.00View SEC Filing  
5/12/2015William N BrittonDirectorSell13,000$21.31$277,030.00View SEC Filing  
3/4/2015Douglas A RothCFOSell5,000$20.99$104,950.00View SEC Filing  
3/4/2015Natasha GiordanoDirectorSell2,164$20.92$45,270.88View SEC Filing  
2/12/2015Douglas A RothCFOSell6,000$19.91$119,460.00View SEC Filing  
2/10/2015Charles John AlaimoSVPSell2,000$20.15$40,300.00View SEC Filing  
12/9/2014Frank DebenedittisVPSell3,000$21.25$63,750.00View SEC Filing  
12/5/2014Douglas A RothCFOSell7,000$22.07$154,490.00View SEC Filing  
12/3/2014Terry KippleyVPSell1,950$21.35$41,632.50View SEC Filing  
12/2/2014Terry KippleyVPSell1,797$21.45$38,545.65View SEC Filing  
12/1/2014Satish SrinivasanCOOSell1,430$21.00$30,030.00View SEC Filing  
11/11/2014Charles John AlaimoSVPSell2,250$21.22$47,745.00View SEC Filing  
9/9/2014Douglas A RothCFOSell6,000$21.57$129,420.00View SEC Filing  
9/9/2014Natasha GiordanoDirectorSell1,453$21.94$31,878.82View SEC Filing  
9/9/2014Raymond BartoneSVPSell3,000$21.49$64,470.00View SEC Filing  
9/9/2014Steven RogersVPSell8,335$21.50$179,202.50View SEC Filing  
9/2/2014Albert L EilenderChairmanSell7,144$19.14$136,736.16View SEC Filing  
8/29/2014Hans C NoetzliDirectorSell2,000$18.85$37,700.00View SEC Filing  
8/15/2014Hans C NoetzliDirectorSell2,000$18.63$37,260.00View SEC Filing  
8/4/2014Albert L EilenderChairmanSell4,195$16.71$70,098.45View SEC Filing  
8/1/2014Hans C NoetzliDirectorSell2,000$16.67$33,340.00View SEC Filing  
7/25/2014Albert L EilenderChairmanSell2,450$17.63$43,193.50View SEC Filing  
7/3/2014Hans C NoetzliDirectorSell2,000$17.86$35,720.00View SEC Filing  
7/2/2014Albert L EilenderChairmanSell1,750$18.05$31,587.50View SEC Filing  
6/6/2014Charles John AlaimoSVPSell2,000$17.51$35,020.00View SEC Filing  
6/6/2014Natasha GiordanoDirectorSell1,160$17.28$20,044.80View SEC Filing  
6/6/2014Steven RogersVPSell2,333$17.58$41,014.14View SEC Filing  
6/4/2014Frank DebenedittisVPSell30,000$17.09$512,700.00View SEC Filing  
6/4/2014Nicolas I ShackleyInsiderSell1,000$17.29$17,290.00View SEC Filing  
6/2/2014Douglas A RothCFOSell6,500$17.10$111,150.00View SEC Filing  
6/2/2014Natasha GiordanoDirectorSell1,149$17.43$20,027.07View SEC Filing  
5/23/2014Natasha GiordanoDirectorSell1,128$17.91$20,202.48View SEC Filing  
5/21/2014Natasha GiordanoDirectorSell1,110$17.81$19,769.1012,942View SEC Filing  
3/10/2014Terry KippleyVPSell3,817$19.17$73,171.8915,689View SEC Filing  
2/14/2014Roger Weaving, Jr.SVPSell6,000$18.96$113,760.0051,296View SEC Filing  
11/12/2013Roger Weaving, Jr.SVPSell14,605$19.03$277,933.1545,918View SEC Filing  
9/6/2013Raymond BartoneSVPSell19,000$14.84$281,960.00View SEC Filing  
6/7/2013Roger Weaving JrVPSell4,420$13.02$57,548.40View SEC Filing  
6/6/2013Guillaume Saint-ClairVPSell15,332$13.01$199,469.32View SEC Filing  
6/4/2013Douglas A RothCFOSell30,000$13.31$399,300.00View SEC Filing  
6/4/2013Eis Jan VanDirectorSell9,000$13.39$120,510.00View SEC Filing  
5/24/2013Ronald GoldCOOSell25,000$11.71$292,750.00View SEC Filing  
5/22/2013Frank DebenedittisVPSell8,300$11.86$98,438.00View SEC Filing  
5/21/2013Frank DebenedittisVPSell7,867$12.00$94,404.00View SEC Filing  
5/17/2013Douglas A RothCFOSell20,200$11.31$228,462.00View SEC Filing  
5/17/2013Guillaume Saint-ClairVPSell2,250$11.15$25,087.50View SEC Filing  
5/15/2013Ronald GoldCOOSell55,000$11.23$617,650.00View SEC Filing  
5/14/2013David B RosenVPSell40,000$11.05$442,000.00View SEC Filing  
5/14/2013Roger Weaving JrSVPSell5,600$11.09$62,104.00View SEC Filing  
(Data available from 1/1/2013 forward)


Aceto (NASDAQ ACET) News Headlines

Aceto (ACET) Cut to Sell at Canaccord GenuityAceto (ACET) Cut to Sell at Canaccord Genuity - April 19 at 10:01 AM
Canaccord Genuity Double Downgrades Aceto Corp. (ACET) to SellCanaccord Genuity Double Downgrades Aceto Corp. (ACET) to Sell - April 19 at 9:41 AM
ACETO Corp (ACET) Said Guidance Should No Longer Be Relied Upon, Anticipates Significant Reduction of DividendACETO Corp (ACET) Said Guidance Should No Longer Be Relied Upon, Anticipates 'Significant' Reduction of Dividend - April 19 at 9:41 AM
BRIEF-ACETO Board Takes Proactive Steps To Address Business And Financial ChallengesBRIEF-ACETO Board Takes Proactive Steps To Address Business And Financial Challenges - April 19 at 9:41 AM
Aceto slumps 51% premarket as business deterioratesAceto slumps 51% premarket as business deteriorates - April 19 at 9:41 AM
Acetos stock plunges to pace premarket losers after credit waiver talks, dividend cutAceto's stock plunges to pace premarket losers after credit waiver talks, dividend cut - April 19 at 9:41 AM
Aceto (ACET) Lowered to Hold at BidaskClubAceto (ACET) Lowered to Hold at BidaskClub - April 18 at 6:54 PM
Head-To-Head Comparison: Cardinal Health (CAH) and Aceto (ACET)Head-To-Head Comparison: Cardinal Health (CAH) and Aceto (ACET) - April 17 at 9:38 AM
McKesson (MCK) and Aceto (ACET) Financial ReviewMcKesson (MCK) and Aceto (ACET) Financial Review - April 16 at 3:17 PM
Aceto (ACET) Research Coverage Started at Canaccord GenuityAceto (ACET) Research Coverage Started at Canaccord Genuity - April 15 at 9:45 AM
Comparing Aceto (ACET) and AmerisourceBergen (ABC)Comparing Aceto (ACET) and AmerisourceBergen (ABC) - April 10 at 5:19 PM
Contrasting Cardinal Health (CAH) & Aceto (ACET)Contrasting Cardinal Health (CAH) & Aceto (ACET) - April 7 at 10:11 AM
Analyzing Aceto (ACET) and Cardinal Health (CAH)Analyzing Aceto (ACET) and Cardinal Health (CAH) - April 4 at 11:20 AM
Critical Comparison: Nu Skin Enterprises (NUS) & Aceto (ACET)Critical Comparison: Nu Skin Enterprises (NUS) & Aceto (ACET) - April 2 at 9:30 AM
Aceto (ACET) Earns Buy Rating from Canaccord GenuityAceto (ACET) Earns Buy Rating from Canaccord Genuity - April 1 at 7:35 PM
Aceto (ACET) Downgraded to "Hold" at ValuEngineAceto (ACET) Downgraded to "Hold" at ValuEngine - March 31 at 4:22 PM
Aceto (ACET) Lifted to "Sell" at BidaskClubAceto (ACET) Lifted to "Sell" at BidaskClub - March 30 at 6:15 PM
Aceto (ACET) Upgraded to "Hold" at Zacks Investment ResearchAceto (ACET) Upgraded to "Hold" at Zacks Investment Research - March 29 at 9:36 PM
Head to Head Review: Meridian Bioscience (VIVO) & Aceto (ACET)Head to Head Review: Meridian Bioscience (VIVO) & Aceto (ACET) - March 26 at 5:23 PM
Aceto (ACET) Downgraded by ValuEngineAceto (ACET) Downgraded by ValuEngine - March 25 at 9:16 PM
World Acetone Markets 2018-2022World Acetone Markets 2018-2022 - March 19 at 5:52 AM
Financial Analysis: Aceto (ACET) vs. AstraZeneca (AZN)Financial Analysis: Aceto (ACET) vs. AstraZeneca (AZN) - March 16 at 11:12 PM
Why Aceto Corporation (NASDAQ:ACET) Should Be In Your PortfolioWhy Aceto Corporation (NASDAQ:ACET) Should Be In Your Portfolio - March 15 at 9:35 AM
Best Healthcare Dividend Stock PicksBest Healthcare Dividend Stock Picks - March 9 at 10:16 AM
Financial Review: Pacira Pharmaceuticals (PCRX) & Aceto (ACET)Financial Review: Pacira Pharmaceuticals (PCRX) & Aceto (ACET) - March 5 at 5:14 AM
Systematic Financial Management LP Has $1.49 Million Position in Aceto Co. (ACET)Systematic Financial Management LP Has $1.49 Million Position in Aceto Co. (ACET) - February 28 at 5:40 PM
ACETO to Appeal U.S. Government Ruling Regarding Certain Lucid Pharma ContractsACETO to Appeal U.S. Government Ruling Regarding Certain Lucid Pharma Contracts - February 28 at 9:35 AM
Citadel Advisors LLC Trims Holdings in Aceto Co. (ACET)Citadel Advisors LLC Trims Holdings in Aceto Co. (ACET) - February 26 at 12:02 PM
Royce & Associates LP Boosts Holdings in Aceto Co. (ACET)Royce & Associates LP Boosts Holdings in Aceto Co. (ACET) - February 25 at 11:28 AM
Head to Head Survey: Aceto (ACET) & Pernix Therapeutics (PTX)Head to Head Survey: Aceto (ACET) & Pernix Therapeutics (PTX) - February 19 at 5:10 AM
Aceto (ACET) Rating Reiterated by Canaccord GenuityAceto (ACET) Rating Reiterated by Canaccord Genuity - February 16 at 4:20 PM
ACETO Appoints Edward J. Borkowski Chief Financial OfficerACETO Appoints Edward J. Borkowski Chief Financial Officer - February 16 at 9:16 AM
Stock Traders Purchase Large Volume of Aceto Put Options (ACET)Stock Traders Purchase Large Volume of Aceto Put Options (ACET) - February 15 at 6:38 AM
ACETO Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25mg, 50mg and 100mgACETO Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25mg, 50mg and 100mg - February 8 at 9:02 AM
Aceto (ACET) Cut to Strong Sell at Zacks Investment ResearchAceto (ACET) Cut to Strong Sell at Zacks Investment Research - February 6 at 4:34 PM
First Analysis Comments on Aceto Co.s FY2018 Earnings (ACET)First Analysis Comments on Aceto Co.'s FY2018 Earnings (ACET) - February 6 at 10:48 AM
Free Research Report as Air Products’ Sales Surged 18%; Non-GAAP Earnings 23%Free Research Report as Air Products’ Sales Surged 18%; Non-GAAP Earnings 23% - February 6 at 9:00 AM
Aceto (ACET) Receives Buy Rating from Canaccord GenuityAceto (ACET) Receives Buy Rating from Canaccord Genuity - February 5 at 6:46 AM
Why Aceto Corporation's Shares Plunged 17% TodayWhy Aceto Corporation's Shares Plunged 17% Today - February 2 at 4:44 PM
Why Aceto Corporations Shares Plunged 17% TodayWhy Aceto Corporation's Shares Plunged 17% Today - February 2 at 12:51 PM
ACETO Reports Fiscal 2018 Second Quarter ResultsACETO Reports Fiscal 2018 Second Quarter Results - February 2 at 9:01 AM
Aceto (ACET) Releases FY18 Earnings GuidanceAceto (ACET) Releases FY18 Earnings Guidance - February 1 at 9:14 PM
Aceto (ACET) Posts  Earnings Results, Misses Expectations By $0.01 EPSAceto (ACET) Posts Earnings Results, Misses Expectations By $0.01 EPS - February 1 at 9:14 PM
Aceto Co. to Issue Quarterly Dividend of $0.07 (ACET)Aceto Co. to Issue Quarterly Dividend of $0.07 (ACET) - February 1 at 3:16 PM
Aceto Corporation declares $0.065 dividendAceto Corporation declares $0.065 dividend - February 1 at 2:37 PM
Why Aceto Corporation (NASDAQ:ACET) Could Be A BuyWhy Aceto Corporation (NASDAQ:ACET) Could Be A Buy - January 31 at 4:37 PM
Aceto Co. (ACET) Given Average Rating of "Hold" by AnalystsAceto Co. (ACET) Given Average Rating of "Hold" by Analysts - January 28 at 1:34 AM
Aceto (ACET) Scheduled to Post Earnings on ThursdayAceto (ACET) Scheduled to Post Earnings on Thursday - January 25 at 1:26 AM
Nova Molecular Technologies a Major Player in the Acetonitrile MarketNova Molecular Technologies a Major Player in the Acetonitrile Market - January 22 at 7:25 PM
Analyzing Aceto (ACET) and Celgene (CELG)Analyzing Aceto (ACET) and Celgene (CELG) - January 19 at 7:37 AM

SEC Filings

Aceto (NASDAQ:ACET) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Aceto (NASDAQ:ACET) Income Statement, Balance Sheet and Cash Flow Statement


Aceto (NASDAQ ACET) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.